PARP Inhibition Changes Individualized Treatment in Advanced

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.

Related Keywords

United States , Texas , Louisiana , Chad , New Orleans , California , American , Dilip Solanki , Lars Neumann , Los Angeles , End Results Program , National Cancer Institute , American Society Of Clinical Oncology , Genomics Education Programme , National Cancer Institute Surveillance , American Cancer Society , Ochsner Cancer Institute , University Of California , American Cancer , American Society , Clinical Oncology , Ritu Salani , Case Based Roundtable , Texas Oncology , Medical Oncology Gynaecological Cancers Congress , Updated January , Statistics Review , Cancer Institute Surveillance , End Results , Updated November , Epidemiol Biomarkers , Update March , Views Vis , Mouret Reynierm A , Parp Inhibitor , Niraparib , Olaparib , Brca , Brca1 , Brca2 , Asomatic , Germline , Fhrd , Homologous Recombination Deficient ,